NEW YORK (GenomeWeb) – Agilent Technologies announced today that its Dako PD-L1 IHC 28-8 pharmDx test, a companion diagnostic for Bristol-Myers Squibb's cancer drug Opdivo (nivolumab), has has received an expanded CE mark for use in Europe.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.